乙型肝炎病毒Pre-S突变体作为生物标志物和肝细胞癌发展和复

StephenW

Hepatitis B Virus Pre-S Mutants as Biomarkers and Targets for the Development and Recurrence of Hepatocellular Carcinoma byChiao-Fang Teng 1,2,3,*
, Han-Chieh Wu 4
, Ih-Jen Su 5,*
and Long-Bin Jeng 2,*




1
Graduate Institute of Biomedical Sciences, China Medical University, No.91, Hsueh-Shih Rd., Northern Dist., Taichung City 404, Taiwan

2
Organ Transplantation Center, China Medical University Hospital, No.2, Yude Rd., North Dist., Taichung City 404, Taiwan

3
Research Center for Cancer Biology, China Medical University, Taichung City 404, Taiwan

4
National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan 350, Taiwan

5
Department of Biotechnology, Southern Taiwan University of Science and Technology, No.1, Nantai St., Yongkang Dist., Tainan City 710, Taiwan

*
Authors to whom correspondence should be addressed.



Viruses 2020, 12(9), 945; https://doi.org/10.3390/v12090945
Received: 24 July 2020 / Revised: 6 August 2020 / Accepted: 25 August 2020 / Published: 26 August 2020
(This article belongs to the Special Issue Viral Molecular Epidemiology)
View Full-TextDownload PDFBrowse Figure

Cite This Paper

Abstract
Chronic hepatitis B virus (HBV) infection is a major risk factor for the development of hepatocellular carcinoma (HCC), the leading cause of cancer-related death worldwide. Despite progress in the prevention and therapy of HCC, high incidence and recurrence rates of HCC remain big threats, resulting in poor patient survival. Effective biomarkers and targets of HCC are therefore urgently needed for better management and to improve patient outcomes. Pre-S mutants have been well demonstrated as HBV oncoproteins that play important roles in HCC development through activation of multiple oncogenic signal pathways in hepatocytes, in vitro and in vivo. The presence of pre-S mutants in patients with chronic HBV infection and HBV-related HCC has been associated with a significantly higher risk of HCC development and recurrence after curative surgical resection, respectively. In this review, we summarize the roles of pre-S mutants as biomarkers for predicting HBV-related HCC development and recurrence, and highlight the pre-S mutants-activated oncogenic signal pathways as potential targets for preventing HBV-related HCC development.View Full-Text
Keywords: hepatitis B virus; hepatocellular carcinoma; biomarkers; targets; pre-S mutants
▼Show Figures
Figure 1




This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

StephenW

乙型肝炎病毒Pre-S突变体作为生物标志物和肝细胞癌发展和复发的目标。
滕乔芳1,2,3，* [OrcID]，吴汉捷4 [OrcID]，Ih-Sen Su 5，*和Long-Bin Jeng 2，*
1个
404台湾台中市北区学事路91号中国医科大学生物医学研究所
2
404台湾台中市北区育德路2号中国医科大学附属医院器官移植中心
3
中国医科大学肿瘤生物学研究中心，台湾台中市404
4
国立卫生研究院国立传染病与疫苗研究所，台湾竹南350
5
台湾南部科技大学生物技术系，台湾台南市永康区南泰街1号，台湾710
*
应与之联系的作者。
病毒2020，12（9），945; https://doi.org/10.3390/v12090945
收到：2020年7月24日/修订：2020年8月6日/接受：2020年8月25日/发布：2020年8月26日
（本文属于特刊病毒分子流行病学）
查看全文下载PDF浏览图
引用本文
抽象
慢性乙型肝炎病毒（HBV）感染是发生肝细胞癌（HCC）的主要危险因素，而肝细胞癌是全球癌症相关死亡的主要原因。尽管在肝癌的预防和治疗方面取得了进展，但是肝癌的高发病率和复发率仍然是巨大的威胁，导致患者存活率低下。因此，迫切需要有效的肝癌生物标志物和靶标，以更好地管理和改善患者预后。 Pre-S突变体已被证明是HBV癌蛋白，可通过在体内和体外激活肝细胞中的多种致癌信号途径在肝癌的发展中发挥重要作用。慢性HBV感染和HBV相关HCC患者中存在pre-S突变体分别与治愈性手术切除后HCC发生和复发的风险显着相关。在这篇综述中，我们总结了pre-S突变体作为预测HBV相关的HCC发生和复发的生物标志物的作用，并着重指出了pre-S突变体激活的致癌信号途径是预防HBV相关的HCC发生的潜在靶标。查看全文
关键词：乙型肝炎病毒；肝细胞癌；生物标志物目标；前S突变体
▼显示数字

图1
这是根据知识共享署名许可协议分发的开放获取文章，只要适当引用了原始作品，该许可就可以在任何介质中无限制地使用，分发和复制

StephenW

https://www.mdpi.com/1999-4915/12/9/945/htm